Provided by Tiger Trade Technology Pte. Ltd.

Sangamo Therapeutics Inc

0.4402
+0.01483.48%
Post-market: 0.45000.0098+2.23%17:46 EST
Volume:30.44M
Turnover:14.46M
Market Cap:148.12M
PE:-0.99
High:0.4783
Open:0.4679
Low:0.4210
Close:0.4254
52wk High:2.84
52wk Low:0.3846
Shares:336.49M
Float Shares:295.00M
Volume Ratio:5.68
T/O Rate:10.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4450
EPS(LYR):-0.4856
ROE:-480.02%
ROA:-68.11%
PB:23.73
PE(LYR):-0.91

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing

Reuters
·
Yesterday

BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain

Reuters
·
Yesterday

Sangamo Therapeutics Shares up 9.3% Premarket After Co Receives U.S. FDA Fast Track Designation for Its Experimental Treatment for Chronic Nerve Pain

THOMSON REUTERS
·
Yesterday

BRIEF-Sangamo Therapeutics Receives U.S. FDA Fast Track Designation For ST-503

Reuters
·
Yesterday

Sangamo Therapeutics Inc - Expects to Dose First Phase 1/2 Stand Study Patient in the Coming Months

THOMSON REUTERS
·
Yesterday

Vera Therapeutics Appoints James R. Meyers to Board of Directors

Reuters
·
Nov 27

Sangamo announces FDA acceptance of BLA rolling submission request for ST-920

TIPRANKS
·
Nov 21

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

TIPRANKS
·
Nov 07

Sangamo Therapeutics Inc. : Barclays Cuts Target Price to $1 From $5

THOMSON REUTERS
·
Nov 07

Sangamo Q3 2025 Earnings Call Summary and Q&A Highlights: Advancing Clinical Pipeline and Regulatory Progress

Earnings Call
·
Nov 07

Sangamo (SGMO) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 07

Sangamo Therapeutics Unveils Genomic Medicine Strategy Focused on Neurological Diseases

Reuters
·
Nov 06

Sangamo Therapeutics Q3 revenue falls short, net loss widens

Reuters
·
Nov 06

BRIEF-Sangamo Therapeutics Q3 Operating Expenses USD 36.1 Million

Reuters
·
Nov 06

Sangamo Therapeutics Q3 Adjusted Operating Expenses USD 33 Million

THOMSON REUTERS
·
Nov 06

Sangamo Therapeutics: Financial Guidance for 2025 Reiterated

THOMSON REUTERS
·
Nov 06

Sangamo Therapeutics Inc expected to post breakeven results a share - Earnings Preview

Reuters
·
Nov 04

Sangamo Therapeutics Files Initial Beneficial Ownership Statement for Principal Accounting Officer Nikunj Jain

Reuters
·
Oct 10

There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise

Simply Wall St.
·
Oct 07

BRIEF-Sangamo Therapeutics Appoints Nikunj Jain As Principal Accounting Officer - SEC Filing

Reuters
·
Oct 01